Walgreens Boots Alliance, Inc. WBA
We take great care to ensure that the data presented and summarized in this overview for Walgreens Boots Alliance, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding WBA
View all-
Vanguard Group Inc Valley Forge, PA84.1MShares$988 Million0.01% of portfolio
-
Black Rock Inc. New York, NY70MShares$823 Million0.02% of portfolio
-
State Street Corp Boston, MA43MShares$506 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA29.9MShares$352 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA19.8MShares$232 Million0.01% of portfolio
-
Morgan Stanley New York, NY14.2MShares$167 Million0.01% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA11MShares$129 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY8.08MShares$95 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL7.59MShares$89.3 Million0.02% of portfolio
-
Northern Trust Corp Chicago, IL7.49MShares$88.1 Million0.01% of portfolio
Latest Institutional Activity in WBA
Top Purchases
Top Sells
About WBA
Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. As of August 31, 2021, this segment operated 8,965 retail stores under the Walgreens and Duane Reade brands in the United States; and five specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2021, this segment operated 4,031 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 548 optical practices, including 160 on a franchise basis. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.
Insider Transactions at WBA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2024
|
Tracey D Brown EVP, Pres., Walgreens Retail |
SELL
Payment of exercise price or tax liability
|
Direct |
16,120
-1.52%
|
$145,080
$9.46 P/Share
|
|
Nov 01
2024
|
Tracey D Brown EVP, Pres., Walgreens Retail |
BUY
Grant, award, or other acquisition
|
Direct |
167,647
+31.92%
|
-
|
|
Nov 01
2024
|
Timothy C Wentworth Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
78,142
-5.68%
|
$703,278
$9.46 P/Share
|
|
Nov 01
2024
|
Timothy C Wentworth Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
762,032
+35.63%
|
-
|
|
Nov 01
2024
|
Manmohan Mahajan EVP and Global CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,220
-0.42%
|
$46,980
$9.46 P/Share
|
|
Nov 01
2024
|
Manmohan Mahajan EVP and Global CFO |
BUY
Grant, award, or other acquisition
|
Direct |
243,316
+36.72%
|
-
|
|
Nov 01
2024
|
Beth Amber L. Fabbri Chief Corp. Affairs Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,967
-3.12%
|
$35,703
$9.46 P/Share
|
|
Nov 01
2024
|
Beth Amber L. Fabbri Chief Corp. Affairs Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,193
+36.23%
|
-
|
|
Nov 01
2024
|
Mary Langowksi EVP, President U.S. Healthcare |
BUY
Grant, award, or other acquisition
|
Direct |
256,684
+33.07%
|
-
|
|
Nov 01
2024
|
Lanesha Minnix EVP and Global CLO |
BUY
Grant, award, or other acquisition
|
Direct |
166,310
+31.79%
|
-
|
|
Nov 01
2024
|
Neal J. Sample EVP, Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,195
-2.79%
|
$199,755
$9.46 P/Share
|
|
Nov 01
2024
|
Neal J. Sample EVP, Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
193,583
+32.51%
|
-
|
|
Nov 01
2024
|
William H Shrank Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,523
+50.0%
|
-
|
|
Nov 01
2024
|
Todd Heckman SVP, Global Controller and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,436
-0.86%
|
$21,924
$9.46 P/Share
|
|
Nov 01
2024
|
Todd Heckman SVP, Global Controller and CAO |
BUY
Grant, award, or other acquisition
|
Direct |
50,802
+34.89%
|
-
|
|
Nov 01
2024
|
Richard P. Gates SVP, Chief Pharmacy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,135
-1.39%
|
$55,215
$9.46 P/Share
|
|
Nov 01
2024
|
Richard P. Gates SVP, Chief Pharmacy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,182
+31.59%
|
-
|
|
Nov 01
2024
|
Elizabeth Burger EVP, Global Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,059
+32.08%
|
-
|
|
Nov 01
2024
|
Thomas E Polen Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,799
+47.29%
|
-
|
|
Nov 01
2024
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,141
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.67M shares |
|---|---|
| Open market or private purchase | 13.5K shares |
| Payment of exercise price or tax liability | 185K shares |
|---|---|
| Open market or private sale | 15.2K shares |